Skip to main content
. 2003 Oct 15;23(28):9418–9427. doi: 10.1523/JNEUROSCI.23-28-09418.2003

Figure 1.

Figure 1.

Survival, body weight, and motor performance analysis in sodium butyrate (SB)-treated R6/2 mice. Cohorts of R6/2 mice (n = 20) were treated from day 21 with an intraperitoneal injection of 100, 200, 400, 600, 1200, 5000, and 10,000 mg · kg-1 · d-1 sodium butyrate. Kaplan-Meier probability of survival analyses of sodium butyrate treatments in R6/2 mice and PBS-treated R6/2 mice are presented in A. Survival was significantly extended in all sodium butyrate dosing paradigms except the 100 mg · kg-1 · d-1 dose, with the greatest increase at the 1200 mg · kg-1 · d-1 dose. The data for the 5000 and 10,000 mg · kg-1 · d-1 doses resulted in marked rapidly coursing morbidity and mortality at on set of treatment and are not included. Effects of intraperitoneal sodium butyrate treatment on body weight in R6/2 HD transgenic mice are shown in B. A significant reduction in body weight loss was observed only after 12 weeks of age. Effects of intraperitoneal sodium butyrate treatment on rotarod performance (C) significantly improved motor performance in R6/2 HD transgenic mice throughout the temporal sequence of the experiment at each of the doses tested. *p < 0.01; **p < 0.001.